https://www.optimumcomms.com/wp-content/uploads/2025/07/Actithera-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-03 08:34:202025-12-03 08:34:20Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
https://www.optimumcomms.com/wp-content/uploads/2025/07/Actithera-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-12-03 08:34:202025-12-03 08:34:20Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer
Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market
Up to €37.5m investment from the EIB, consisting of €10m…

Neuraxpharm and mjn-neuro announce plans to launch EPISERAS®, a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
A non-invasive, AI-based, wearable earpiece that continuously…

Biocomposites announces expanded approval for STIMULAN® Rapid Cure to be mixed with antimicrobials to treat infection
STIMULAN® Rapid Cure can now be used with both a wider range…

Poolbeg Pharma plc – POLB 001 European Patent granted
Further strengthens Poolbeg's global intellectual property portfolio
20…

Sofinnova Partners closes €650M ($750M) Capital XI, greatly exceeding initial target to back early-stage healthcare deals
Total capital raised across Sofinnova’s platform reaches…

Medicxi Announces €500 Million Fund V
New fund will continue Medicxi’s successful asset-centric company…

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer
Internationally recognized clinical strategist with proven…

Blue Cell Therapeutics appoints leading cell therapy executive Miguel Forte MD, PhD, to its Board of Directors
Miguel Forte, current President of the International Society…

Commit Biologics achieves proof-of-concept for novel Complement Engager platform in non-human primates
Novel approach harnessing the power of the complement system…

Leucid Bio Provides Update on Phase I/IIa AERIAL Trial Evaluating Lateral CAR-T LEU011 for the Treatment of Solid Tumours
Proof-of-concept established for LEU011 in the treatment…

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025
New clinical data from the MATCH Phase II study shows early…

Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Evidence of clinical activity observed in Cohort 8, including…

Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell
Groundbreaking research using Nucleome MCC technology reveals…

Amber Implants Appoints Vincent Gardès as Chief Executive Officer to Drive Commercial Launch of VCFix® Spinal System
Experienced MedTech leader to guide Amber Implants' transition…

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform
AmacaThera receives US$5 million upfront and up to US$225…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York